UBS Group’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $13.1M | Sell |
216,000
-1,464,593
| -87% | -$85.4M | ﹤0.01% | 3055 |
|
|
2025
Q4 | $90.7M | Buy |
1,680,593
+219,100
| +15% | +$10.5M | 0.01% | 1089 |
|
|
2025
Q3 | $65.9M | Buy |
1,461,493
+914,393
| +167% | +$42.7M | 0.01% | 1375 |
|
|
2025
Q2 | $25.3M | Buy |
547,100
+214,000
| +64% | +$10.5M | ﹤0.01% | 2131 |
|
|
2025
Q1 | $20.3M | Sell |
333,100
-934,500
| -74% | -$54.5M | ﹤0.01% | 2306 |
|
|
2024
Q4 | $71.7M | Buy |
1,267,600
+329,700
| +35% | +$18.4M | 0.01% | 1158 |
|
|
2024
Q3 | $48.5M | Buy |
937,900
+295,700
| +46% | +$13.9M | 0.01% | 1167 |
|
|
2024
Q2 | $26.7M | Buy |
642,200
+105,000
| +20% | +$4.7M | 0.01% | 1456 |
|
|
2024
Q1 | $29.1M | Sell |
537,200
-1,548,800
| -74% | -$78.9M | 0.01% | 1408 |
|
|
2023
Q4 | $107M | Buy |
2,086,000
+185,800
| +10% | +$9.75M | 0.03% | 547 |
|
|
2023
Q3 | $110M | Buy |
1,900,200
+238,100
| +14% | +$14.6M | 0.04% | 464 |
|
|
2023
Q2 | $106M | Sell |
1,662,100
-174,600
| -10% | -$11.7M | 0.04% | 473 |
|
|
2023
Q1 | $127M | Sell |
1,836,700
-945,200
| -34% | -$66.7M | 0.05% | 380 |
|
|
2022
Q4 | $200M | Buy |
2,781,900
+943,000
| +51% | +$71.1M | 0.07% | 278 |
|
|
2022
Q3 | $131M | Buy |
1,838,900
+171,800
| +10% | +$12.5M | 0.06% | 331 |
|
|
2022
Q2 | $128M | Buy |
1,667,100
+27,500
| +2% | +$2.09M | 0.05% | 366 |
|
|
2022
Q1 | $120M | Sell |
1,639,600
-111,400
| -6% | -$7.48M | 0.04% | 459 |
|
|
2021
Q4 | $109M | Buy |
1,751,000
+519,802
| +42% | +$30.5M | 0.03% | 556 |
|
|
2021
Q3 | $72.8M | Sell |
1,231,198
-160,500
| -12% | -$10.6M | 0.02% | 674 |
|
|
2021
Q2 | $93M | Buy |
1,391,698
+100,900
| +8% | +$6.58M | 0.03% | 551 |
|
|
2021
Q1 | $81.5M | Sell |
1,290,798
-623,202
| -33% | -$38.8M | 0.03% | 595 |
|
|
2020
Q4 | $119M | Buy |
1,914,000
+755,000
| +65% | +$46.4M | 0.04% | 423 |
|
|
2020
Q3 | $69.9M | Buy |
1,159,000
+135,800
| +13% | +$8.17M | 0.03% | 517 |
|
|
2020
Q2 | $60.2M | Sell |
1,023,200
-107,300
| -9% | -$6.42M | 0.03% | 534 |
|
|
2020
Q1 | $63M | Sell |
1,130,500
-763,921
| -40% | -$46.7M | 0.03% | 461 |
|
|
2019
Q4 | $122M | Buy |
1,894,421
+671,521
| +55% | +$38.5M | 0.04% | 388 |
|
|
2019
Q3 | $62M | Buy |
1,222,900
+285,400
| +30% | +$13.4M | 0.02% | 580 |
|
|
2019
Q2 | $42.5M | Buy |
937,500
+385,800
| +70% | +$18M | 0.02% | 753 |
|
|
2019
Q1 | $26.3M | Sell |
551,700
-477,100
| -46% | -$23.8M | 0.01% | 980 |
|
|
2018
Q4 | $53.5M | Sell |
1,028,800
-13,400
| -1% | -$720K | 0.02% | 571 |
|
|
2018
Q3 | $64.7M | Buy |
1,042,200
+1,500
| +0.1% | +$89K | 0.03% | 560 |
|
|
2018
Q2 | $57.6M | Buy |
1,040,700
+392,800
| +61% | +$21.2M | 0.02% | 587 |
|
|
2018
Q1 | $41M | Sell |
647,900
-281,700
| -30% | -$18.1M | 0.02% | 734 |
|
|
2017
Q4 | $57M | Buy |
929,600
+200,300
| +27% | +$12.5M | 0.02% | 616 |
|
|
2017
Q3 | $46.5M | Sell |
729,300
-316,100
| -30% | -$18.5M | 0.02% | 626 |
|
|
2017
Q2 | $58.3M | Sell |
1,045,400
-245,300
| -19% | -$13.3M | 0.03% | 521 |
|
|
2017
Q1 | $70.2M | Buy |
1,290,700
+609,400
| +89% | +$33.4M | 0.04% | 432 |
|
|
2016
Q4 | $39.8M | Buy |
681,300
+278,062
| +69% | +$15.2M | 0.02% | 647 |
|
|
2016
Q3 | $21.7M | Buy |
403,238
+278,738
| +224% | +$17.9M | 0.01% | 924 |
|
|
2016
Q2 | $9.16M | Buy |
124,500
+7,500
| +6% | +$530K | 0.01% | 1448 |
|
|
2016
Q1 | $7.47M | Sell |
117,000
-511,500
| -81% | -$32.3M | 0.01% | 1531 |
|
|
2015
Q4 | $43.2M | Buy |
628,500
+239,600
| +62% | +$15.8M | 0.03% | 551 |
|
|
2015
Q3 | $23M | Buy |
388,900
+56,200
| +17% | +$3.57M | 0.02% | 810 |
|
|
2015
Q2 | $22.1M | Buy |
332,700
+15,200
| +5% | +$1M | 0.01% | 911 |
|
|
2015
Q1 | $20.5M | Sell |
317,500
-92,300
| -23% | -$5.78M | 0.01% | 943 |
|
|
2014
Q4 | $24.2M | Buy |
+409,800
| New | +$23.1M | 0.02% | 881 |
|
Other funds holding BMY
VCM
VPM
UBS Group's BMY Position: Q1 2026 in Review
UBS Group increased its Bristol-Myers Squibb (BMY) stake by 17% in Q1 2026, buying an estimated $61.2M and bringing the position to 7,200,449 shares worth $437M. The position accounts for 0.07% of the portfolio, ranked #301.
UBS Group first reported a position in BMY in Q4 2014 and has held it in 46 quarters since. The position peaked at $652M in Q4 2019. 2,519 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- UBS Group held 7,200,449 shares of Bristol-Myers Squibb worth $437M as of Q1 2026.
- UBS Group bought 1,049,337 Bristol-Myers Squibb shares in Q1 2026, an estimated $61.2M.
- Bristol-Myers Squibb made up 0.07% of UBS Group's portfolio in Q1 2026, its #301 holding.
- UBS Group first reported a position in Bristol-Myers Squibb in Q4 2014 and has held it in 46 quarters since.
- UBS Group's Bristol-Myers Squibb position peaked at $652M in Q4 2019.
- 2,519 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.